Radiopharm Theranostics (RDPTF) Cost of Revenue (2024 - 2026)
Radiopharm Theranostics' (RDPTF) quarterly Cost of Revenue came in at $335000.6 in Q2 2026, down 90.68% year-over-year from $3.6 million in Q2 2025, and down 90.68% quarter-over-quarter from $3.6 million in Q2 2025.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Cost of Revenue (2024 - 2026) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Cost of Revenue for 3 consecutive years, with $335000.6 the latest figure, recorded in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn | 2.81 Bn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn | 1.58 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | 489.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 360.70 Mn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn | 145.00 Mn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn | 93.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn | 776.90 Mn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | 284,000.00 |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | 335,000.61 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 335,000.61 |
| Jun 30, 2025 | 3.59 Mn |
| Jun 30, 2024 | 213,252.42 |